Schizophrenia/Psychosis

Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.

SIRS highlights new schizophrenia advances: LB-102 shows promise, Cobenfy switching stays stable, and tazbentetol targets synaptic regeneration.

Motivational interviewing can help psychiatrists address long-acting injectable hesitancy in schizophrenia, according to Gerald Maguire, MD.

How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.

Gerald A. Maguire, MD, shares his experience and insights on the importance of trust and empathy.

Open-label phase 2 trial tests IV Briumvi alongside antipsychotics for treatment-resistant schizophrenia, targeting B-cell depletion to improve symptoms and assess safety.

Estrogen shapes schizophrenia in women: onset peaks, dosing shifts, and relapse risk from periods to pregnancy, postpartum, and menopause.

Learn how cognitive remediation, aerobic exercise, and reducing secondary risks can boost thinking skills and daily functioning in schizophrenia.

Key steps for first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction.

Learn a multidimensional approach to suicide prevention in schizophrenia—screening, insight paradox, cannabis, cognition, trauma, and ethical AI monitoring.

New spectral sleep analysis and HD‑tDCS aim to strengthen restorative sleep and memory, offering promise for schizophrenia-related cognitive deficits.

Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.

Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

Curiosity, rapport, and understanding lived experience can strengthen schizophrenia care and treatment engagement, according to Tracy Hicks, DNP.

Explore how integrated psychotherapy—CBTp, family support, and humane alliance—reduces relapse and restores meaning beyond medication in schizophrenia.

Olanzapine-samidorphan keeps olanzapine efficacy yet limits weight gain, boosts negative symptoms, and cuts ER visits in real-world care.

Why schizophrenia shortens life: smoking, metabolic risks, and care gaps drive a 15-year mortality loss—and clinicians can help close it.

Analysis of speech, acoustics, and facial cues reveals early psychosis and suicide risk.

Computational phenotyping reveals prodromal psychosis clues, connects biomarkers to symptoms, and shows why stress and cannabis reduction matters.

Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.

Key schizophrenia facts: early warning signs, brain changes, treatment limits—and how AI could reveal biomarkers for more personalized care.

Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.